Provided by Tiger Fintech (Singapore) Pte. Ltd.

iBio

0.5942
-0.0002-0.03%
Post-market: 0.59970.0055+0.93%19:58 EDT
Volume:452.42K
Turnover:263.36K
Market Cap:9.64M
PE:-0.26
High:0.5999
Open:0.5944
Low:0.5562
Close:0.5944
52wk High:6.89
52wk Low:0.5562
Shares:16.22M
Float Shares:15.17M
Volume Ratio:1.09
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3234
EPS(LYR):-6.5014
ROE:-90.83%
ROA:-30.35%
PB:0.85
PE(LYR):-0.09

Loading ...

iBio Faces Nasdaq Delisting Notice for Stock Price

TIPRANKS
·
Aug 02

iBio Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement

Reuters
·
Aug 02

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 25

iBio, AstralBio unveil obesity program with amylin receptor agonist antibody

TIPRANKS
·
Jun 24

BRIEF-Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Reuters
·
Jun 24

iBio Inc. Announces Extension of Promissory Note with Safi Biotherapeutics, Requires Interest Payment for Extension

Reuters
·
Jun 18

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
Jun 17

BRIEF-IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment

Reuters
·
Jun 16

iBio initiates non-human primate study of IBIO-610

TIPRANKS
·
Jun 16

IBio Files Prospectus for Resale of About 11.3 Million Shares

MT Newswires Live
·
Jun 13

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
May 20

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
May 12

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 05

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

GlobeNewswire
·
May 05

iBio, Inc. Reports Strong Q3 2025 Progress

TIPRANKS
·
May 05

BRIEF-iBio Reports Fiscal Third Quarter 2025 Financial Results

Reuters
·
May 02

iBio Q3 EPS $(0.49) Misses $(0.34) Estimate

Benzinga
·
May 02

Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results

Dow Jones
·
May 02

BRIEF-Ibio Inc Enters Exclusive License Agreement With AstralBio

Reuters
·
Apr 23

iBio Enters Licensing Agreement for Obesity Treatment

TIPRANKS
·
Apr 23